Diligent Efforts Sample Clauses

Diligent Efforts. Pfizer and Xenogen Cranbury each shall use reasonably diligent efforts to achieve the objectives of the Research Program. Xenogen Cranbury will use reasonably diligent efforts to achieve the objectives listed in the Research Plan and Pfizer will use reasonably diligent efforts to assist Xenogen Cranbury in such efforts.

Diligent Efforts. Company, acting itself and/or through its Sublicensees, (i) shall use commercially reasonable, diligent efforts to develop Licensed Products and to bring Licensed Products to market through a thorough, vigorous and diligent program for exploitation of the Licensed Patents and to continue active, diligent marketing efforts for Licensed Products throughout the Term, consistent with sound and reasonable business practices, and (ii) shall endeavor to keep Licensed Products, to the extent commercially reasonable, available to the public.

Diligent Efforts. On a Collaboration Target-by-Collaboration Target basis, Roche and BPM shall each use Commercially Reasonable Efforts to perform their respective tasks and obligations in conducting all activities ascribed to it in the then-current Research Plan for such Collaboration Target in the Field, in accordance with the time parameters set forth therein.

Diligent Efforts. During the Milestone Period, Parent Holdco (and its successors and assigns) shall, and shall cause its (and their) Subsidiaries to, use Diligent Efforts to achieve the Milestone prior to the end of the Milestone Period and as promptly as practicable following the Effective Time.

Diligent Efforts. Parent shall, and shall cause its controlled Affiliates and any other Selling Entity to, use Diligent Efforts to achieve the Third Net Sales Milestone as promptly as practicable prior to the Net Sales Milestone Payment Termination Date.

Diligent Efforts. Clinigen will, in accordance with the priorities agreed by the Joint Steering Committee, exercise Diligent Efforts in pursuing any further required Marketing Authorization Approvals necessary to Commercialize the Licensed Product in each Country of the Territory. Theravance will, in accordance with the priorities agreed by the Joint Steering Committee, exercise Diligent Efforts in providing Clinigen with evidence confirming that there is, within the marketing authorization dossier for the Licensed Product, an authorized manufacturing site which fulfills the requirements set out in Article 41 of Directive 2001/83/EC and otherwise provide Clinigen the information necessary to maintain the Marketing Authorization Approvals. ***CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Diligent Efforts. Rigel and Pfizer each shall use reasonably diligent efforts to achieve the objectives of the Research Program.

Diligent Efforts. Commencing upon the Closing Date and ending on the payment to Seller of Milestone Payments in an amount equal to the Milestone Payment Cap, Purchaser shall, shall cause each Affiliated Payment Obligor to, and shall use its commercially reasonable efforts to cause each other Payment Obligor to (i) subject to the last sentence of this Section 1.05, use Diligent Efforts to Exploit the Compound and the Products in order to achieve Net Sales and (ii) except in a manner that is consistent with the normal business practices of Purchaser and the other Payment Obligors, as applicable, not act in a manner that intentionally reduces Net Sales, including by deferring or delaying the receipt or recognition of any sales of any Product in a manner that is inconsistent with the normal business practices of Purchaser and the other Payment Obligors, as applicable; provided, however, that, subject in all cases to Purchaser’s compliance with its obligations under clause (i) of this Section 1.05, (A) Purchaser shall have the right to pursue the Exploitation of the Products in such a manner as Purchaser shall determine in good faith to be in its best interests, and (B) following (but not prior to) the First Commercial Sale, Purchaser shall have the right to discontinue or delay the Development of the Compound and Products in the event that that Purchaser reasonably determines in good faith that, notwithstanding Purchaser’s use of such Diligent Efforts, further investment in Development of Products would not be reasonably likely to generate a positive return on investment on a risk-adjusted basis. Notwithstanding the foregoing, prior to the First Commercial Sale, Purchaser shall not discontinue or delay the Development of the Compound and Products, including by failing to pay undisputed amounts due under the Transition Services Agreement (provided, that notwithstanding anything herein to the contrary, Purchaser may discontinue or delay such Development at any time if (x) directed to do so on the basis of human safety by any Governmental Entity or the data safety monitoring board for an Ongoing Trial, (y) the Company would not be able to distribute and sell in the United States the Product that is the subject of the Ongoing Trials without infringing any Third Party’s Intellectual Property in existence as of the time of such discontinuation or delay, or (z) [***].

Diligent Efforts. Amarin shall be responsible for (at its own cost) and shall use commercially reasonable efforts to (i) conduct all stage I activities set out in Schedule 5; (ii) conduct any further development activities and any further clinical trials with respect to the Product Intermediate, the Product or any relevant Device to commercialize Product in the Primary Territory and (iii) register, market and promote the Product in the Primary Territory: 8.1.1 in particular in respect of the Primary Territory, Amarin agrees that it, its Affiliates and permitted sub-licensees shall: 8.1.1.1 conduct in an expeditious manner all necessary pre-clinical and clinical studies in respect of the Product Intermediate, the Product and any Device that may be used to administer the Product or Product Intermediate and to conduct such activities in accordance with prevailing cGLP, cGCP and cGMP and, in all material respects, in accordance with all applicable Governmental Authority standards and guidelines; 8.1.1.2 obtain Regulatory Approvals for the Product and all necessary governmental approvals that may need to be obtained for the Device in order to market the Product in the Primary Territory; 8.1.1.3 promote the Product as the flagship brand under Amarin’s prevailing trademark(s) for use in an outpatient setting in repetitive epileptic seizures and for any other indications in a country for which the Product is approved for use in that country and to otherwise use the same level of effort as used by Amarin with other similar products of similar sales potential; 8.1.1.4 market and promote the Product with a view to achieving maximum market impact and concentration throughout the Primary Territory and at least the same level of effort as with other similar products of similar sales potential which it markets; and in the event that Amarin elects to market the Product in any part of the Secondary Territory, the same obligation shall apply to such territory; and 8.1.1.5 comply with all applicable rules and regulations, in all material respects, in regard to the storage, handling, development and commercialization of Product and Product Intermediate and otherwise conduct all storage, handling, development and commercialization activities relating to the Product and Product Intermediate with due care in accordance with normal standards in the pharmaceutical industry.